Key points
Acarbose (Acarphage) is a tablet for high blood sugar that works in the small intestine: it slows the breakdown of starch and sucrose, so glucose after a meal enters the blood gradually, and less than 2 % of the dose is absorbed into the blood itself.
| Situation | How it helps | What human studies showed |
|---|---|---|
| Prediabetes (impaired glucose tolerance) | lowers the risk of progression to type 2 diabetes; more often returns blood sugar to normal | STOP-NIDDM, 1,429 people, 3.3 years: diabetes in 32 % on acarbose vs 42 % on placebo (Chiasson JL Lancet 2002. PMID 12086760); ACE, 6,522 Chinese patients with coronary heart disease and prediabetes, 5 years: 13 % vs 16 % (Holman RR Lancet Diabetes Endocrinol 2017. PMID 28917545) |
| Newly diagnosed type 2 diabetes | lowers HbA1c no worse than metformin | MARCH (China), 788 people, 48 weeks: HbA1c −1.11 % on acarbose vs −1.12 % on metformin (Yang W Lancet Diabetes Endocrinol 2014. PMID 24622668) |
| Weight | does not add weight, on average slightly reduces it | 2023 meta-analysis of RCTs: −1.25 kg vs placebo (Zamani M Front Nutr 2023. PMID 37599681); acarbose at 300 mg/day — 1.23 kg more weight loss than DPP-4 inhibitors with the same HbA1c lowering (Zhang F Front Endocrinol 2020. PMID 32582019) |
| Gut microbiota | changes the bacterial composition: undigested carbohydrates become food for them | in 52 people with prediabetes the share of Lactobacillus, Faecalibacterium and Dialister rose (Zhang X Diabetes Ther 2017. PMID 28130771) |
| Reactive hypoglycaemia (off-label) | flattens the post-meal glucose peak | in a double-blind study of 24 people, 100 mg of acarbose with a sucrose load reduced both the glucose peak and the subsequent dip (Gérard J Int J Clin Pharmacol Ther Toxicol 1984. PMID 6698657) |
| Glucose dips after gastric bypass | may soften the dips | in 11 women the glucose nadir in a mixed-meal test rose from 3.4 to 3.9 mmol/L (from 61 to 70 mg/dL) (Øhrstrøm CC Diabetes Obes Metab 2019. PMID 31144430) |
How it helps
What kind of drug this is
Acarbose is an alpha-glucosidase inhibitor, the best-studied drug of its class. The originator is Bayer's Glucobay, in Europe since the 1990s, sold in the USA as Precose. Acarphage is an Italian generic by Bruno Farmaceutici in 50 and 100 mg tablets; the label «medicinale equivalente» means an equivalent medicine with the same active substance.
Chemically it is a pseudotetrasaccharide — a molecule that looks like a fragment of starch but has one link that enzymes cannot cut. The whole mechanism is built on this resemblance.
How it works: a tablet that never reaches the blood
Almost all glucose-lowering drugs act through the blood: they make the pancreas release insulin, help tissues hear it, remove glucose with the urine or, like imeglimin, change how mitochondria work. Acarbose is built differently. Its target is the alpha-glucosidase enzymes on the brush border of the small intestine, which cut starch, maltose and sucrose into glucose molecules. Only glucose is absorbed into the blood; until a carbohydrate is cut, it stays in the gut lumen.
In plain words. Imagine food as a long string of beads, and the gut wall lets through only single beads. The enzymes are scissors that cut the string. Acarbose looks like a piece of string but «cannot be cut»: the scissors grab it, get stuck for a few seconds and let go. The string will be cut eventually, but more slowly. Glucose enters the blood not as a surge within half an hour but spread over two to three hours, and some carbohydrate reaches the colon undigested.
Two consequences follow, and they explain both the pluses and the minuses. First: the post-meal glucose peak becomes lower and later, and the need for insulin is smaller. Second: the carbohydrates that reach the colon become food for bacteria — with all the consequences in the form of gas, but also with a change in the microbiota, discussed below.
Diabetes prevention: STOP-NIDDM and ACE
STOP-NIDDM is the main prevention trial. People with prediabetes (impaired glucose tolerance) were randomly assigned to acarbose 100 mg three times a day or placebo and checked by glucose tolerance test for over three years. On acarbose, diabetes developed in 221 of 682, on placebo in 285 of 686; relative hazard 0.75 (95 % CI 0.63–0.90) (Chiasson JL Lancet 2002. PMID 12086760). In addition, reversion from prediabetes to normal was more frequent on acarbose.
ACE confirmed prevention in another population: 6,522 Chinese patients with coronary heart disease and prediabetes, acarbose 50 mg three times a day, 5 years of follow-up, 176 clinics. Diabetes developed less often: 13 % vs 16 %, rate ratio 0.82 (Holman RR Lancet Diabetes Endocrinol 2017. PMID 28917545). So diabetes prevention is confirmed twice, in different populations. What else, besides tablets, reverses prediabetes is covered in How to reverse prediabetes: a complete guide.
Newly diagnosed diabetes: MARCH
MARCH answers a different question: can acarbose be the first drug in diabetes, instead of metformin. In 788 people with newly diagnosed type 2 diabetes, over 48 weeks HbA1c fell by 1.11 % on acarbose and 1.12 % on metformin — a 0.01 % difference; hypoglycaemia was rare in both groups (Yang W Lancet Diabetes Endocrinol 2014. PMID 24622668).
Weight
A 2023 meta-analysis of randomised trials: versus placebo, acarbose gives −1.25 kg (95 % CI −1.79 to −0.75) and −0.64 kg/m² of body mass index, lowers HbA1c by 0.32 %, fasting insulin, triglycerides by 13.9 mg/dL (0.16 mmol/L) and systolic blood pressure by 1.3 mmHg (Zamani M Front Nutr 2023. PMID 37599681). A 2020 network meta-analysis with 11,877 participants: with the same HbA1c lowering, acarbose at 300 mg/day gives 1.23 kg more weight loss than DPP-4 inhibitors (Zhang F Front Endocrinol 2020. PMID 32582019).
In plain words. Unlike insulin and sulfonylureas, acarbose does not add weight, and some people on it do lose noticeably more than average — mostly those whose diet was built on starch and sweets.
Microbiota
The carbohydrates acarbose did not let be digested reach the colon and become substrate for bacteria — in effect, the drug acts as a prebiotic. In 52 people with prediabetes in a double-blind crossover trial, acarbose increased the share of Lactobacillus, Faecalibacterium and Dialister, while Butyricicoccus and Ruminococcus decreased (Zhang X Diabetes Ther 2017. PMID 28130771). In patients with newly diagnosed diabetes, acarbose, unlike glipizide, increased the share of Lactobacillus and Bifidobacterium, reduced Bacteroides and shifted the plasma bile acid profile towards primary acids; and those with a Bacteroides-dominated microbiota before treatment responded better (Gu Y Nat Commun 2017. PMID 29176714).
Post-meal glucose dips
Because acarbose flattens the post-meal glucose peak, it has long been used off-label in reactive hypoglycaemia — when 1 to 3 hours after a carbohydrate meal blood sugar drops below normal with tremor, sweating and weakness. In a double-blind study of 24 people, 100 mg of acarbose with a sucrose load reduced both the glucose peak and the subsequent dip (Gérard J Int J Clin Pharmacol Ther Toxicol 1984. PMID 6698657).
After gastric bypass such dips can be especially deep. In 11 women with documented post-bypass hypoglycaemia, acarbose 50 mg raised the glucose nadir in a mixed-meal test from 3.4 to 3.9 mmol/L (from 61 to 70 mg/dL) and shortened the time in hypoglycaemia (Øhrstrøm CC Diabetes Obes Metab 2019. PMID 31144430).
Comparison with metformin and imeglimin
| Acarbose | Metformin | Imeglimin | |
|---|---|---|---|
| Where it acts | Small-intestinal lumen | Liver, muscle (via blood) | Mitochondria (via blood) |
| HbA1c lowering | −1.1 % (MARCH); −0.3 % in meta-analyses vs placebo | −1 to −1.5 % | −0.6 to −0.9 % |
| Weight | −1.2 kg | −1 to −2 kg | Neutral |
| Hypoglycaemia on its own | No | No | No |
| Main side effects | Gas, diarrhoea | Nausea, diarrhoea, B12 deficiency | Nausea, diarrhoea |
| Kidney limit | Clearance < 25 mL/min | eGFR < 30 mL/min | Data down to dialysis |
| Diabetes prevention | Proven (STOP-NIDDM, ACE) | Proven (DPP) | Not studied |
Imeglimin is covered in detail in Imeglimin: a new word in type 2 diabetes treatment. Acarbose's place in this trio is the patient whose main problem is precisely post-meal glucose, who does not want or cannot take metformin, and who is prepared to put up with the first weeks of gas for a drug that never enters the blood.
How to take it
The tablet is taken with the first mouthful of a meal — swallowed whole or chewed: the drug must reach the intestine together with the carbohydrates. Treatment starts at 50 mg one to three times a day and the dose is increased gradually, in steps of several weeks, to the usual maintenance dose of 50–100 mg three times a day; the label maximum is 300 mg per day (in the USA, 150 mg for body weight up to 60 kg). Slow dose escalation is the main way to reduce gas and diarrhoea; the second is to cut sucrose in food, because undigested sucrose produces the most fermentation. The dose and schedule are the doctor's decision; this describes the label, it is not a recommendation.
Who should see a doctor first
Contraindications per the manufacturer's label: inflammatory bowel disease (Crohn's disease, ulcerative colitis), intestinal obstruction or predisposition to it, large hernias, chronic conditions with impaired digestion or absorption, severe renal impairment (creatinine clearance below 25 mL/min), liver cirrhosis, pregnancy, breastfeeding, age under 18. Any of these is a reason not to start.
Hypoglycaemia. Acarbose does not act on glucose or lactose, because those are not its enzymes. If hypoglycaemia occurs on top of insulin or sulfonylureas, it is reversed only with pure glucose — sugar, honey and sweet tea will not work, because the drug will not let sucrose be broken down.
Liver. The US label describes transaminase elevations at high doses, reversible after withdrawal; checking ALT and AST during the first year of treatment is recommended. What these values mean is covered in ALT without symptoms: silent liver diseases.
Interactions. Digestive enzymes, charcoal and other intestinal adsorbents, and cholestyramine reduce the effect; acarbose may change digoxin levels. With insulin and sulfonylureas there is a risk of hypoglycaemia, which is reversed only with glucose.
Gas and diarrhoea are the most common side effects: carbohydrates not broken down in the small intestine reach the bacteria of the colon. In STOP-NIDDM, 31 % of participants on acarbose stopped early versus 19 % on placebo, mostly because of gas and diarrhoea.
What to check before starting: fasting glucose and HbA1c or a glucose tolerance test (so that there is an indication), creatinine with estimated clearance, ALT and AST, and an honest answer to whether there is chronic abdominal pain, diarrhoea or bloating — against that background the drug will be poorly tolerated.
Blood sugar. If you don't have diabetes — repeatedly below 3.0 mmol/L (54 mg/dL) or above 8.9 mmol/L (160 mg/dL): see a doctor; with diabetes, targets are individual (per your doctor's plan), and sugar below 3.0 mmol/L (54 mg/dL) always means seeing a doctor.
Bottom line
Acarbose is a rare case of a drug with a clear mechanism, a thirty-year history and two large trials that agree on one thing: in people with prediabetes it lowers the risk of diabetes by 18–25 %. In newly diagnosed diabetes it matched metformin, it does not add weight and on average slightly reduces it. The price is gas and diarrhoea in the first weeks and the discipline of taking it with every meal.
Acarphage (acarbose 50 mg, 40 tablets) can be ordered in our shop; prescription, dose and lab monitoring are arranged at a consultation.
Source: Acarbose (Acarphage): the tablet that works in the gut, not in the blood — universum.earth. Dr. Pereligyn.
